New lysine methyltransferase drug targets in cancer

Recent preclinical studies suggest that inhibitors of histone methyltransferases represent promising drug candidates for cancer therapy.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature biotechnology 2012-07, Vol.30 (7), p.622-623
Hauptverfasser:	Wagner, Tobias, Jung, Manfred
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/309/2144 631/1647/2210/2212 631/61 692/699/67/1059 Agriculture Antimitotic agents Antineoplastic agents Bioinformatics Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology Cancer Cancer therapies Drug therapy Enhancer of Zeste Homolog 2 Protein Enzyme Inhibitors - therapeutic use Health aspects Histocompatibility Antigens - metabolism Histone-Lysine N-Methyltransferase - antagonists & inhibitors Histone-Lysine N-Methyltransferase - metabolism Histones Humans Life Sciences Methyltransferases Methyltransferases - antagonists & inhibitors Methyltransferases - metabolism Molecular Targeted Therapy Neoplasms - drug therapy news-and-views Physiological aspects Polycomb Repressive Complex 2 - antagonists & inhibitors Polycomb Repressive Complex 2 - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Recent preclinical studies suggest that inhibitors of histone methyltransferases represent promising drug candidates for cancer therapy.
ISSN:	1087-0156 1546-1696
DOI:	10.1038/nbt.2300